Browsing by Author Kakafika, A. I.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 1 to 17 of 17
TitleAuthor(s)Issue date
Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohortAthyros, V. G.; Liberopoulos, E. N.; Mikhailidis, D. P.; Papageorgiou, A. A.; Ganotakis, E. S.; Tziomalos, K.; Kakafika, A. I.; Karagiannis, A.; Lambropoulos, S.; Elisaf, M. S.24-Nov-2015
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek studyAthyros, V. G.; Ganotakis, E. S.; Bathianaki, M.; Monedas, I.; Goudevenos, I. A.; Papageorgiou, A. A.; Papathanasiou, A.; Kakafika, A. I.; Mikhailidis, D. P.; Elisaf, M. S.24-Nov-2015
Dyslipidaemia, hypercoagulability and the metabolic syndromeKakafika, A. I.; Liberopoulos, E. N.; Karagiannis, A.; Athyros, V. G.; Mikhailidis, D. P.24-Nov-2015
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrateChristidis, D. S.; Liberopoulos, E. N.; Kakafika, A. I.; Miltiadous, G. A.; Cariolou, M.; Ganotakis, E. S.; Mikhailidis, D. P.; Elisaf, M. S.24-Nov-2015
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised studyAthyros, V. G.; Mikhailidis, D. P.; Didangelos, T. P.; Giouleme, O. I.; Liberopoulos, E. N.; Karagiannis, A.; Kakafika, A. I.; Tziomalos, K.; Burroughs, A. K.; Elisaf, M. S.24-Nov-2015
Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatinChristidis, D. S.; Liberopoulos, E. N.; Kakafika, A. I.; Miltiadous, G. A.; Liamis, G. L.; Kakaidi, B.; Tselepis, A. D.; Cariolou, M. A.; Elisaf, M. S.24-Nov-2015
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) StudyAthyros, V. G.; Mikhailidis, D. P.; Liberopoulos, E. N.; Kakafika, A. I.; Karagiannis, A.; Papageorgiou, A. A.; Tziomalos, K.; Ganotakis, E. S.; Elisaf, M. S.24-Nov-2015
Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE studyAthyros, V. G.; Mikhailidis, D. P.; Papageorgiou, A. A.; Bouloukos, V. I.; Pehlivanidis, A. N.; Symeonidis, A. N.; Kakafika, A. I.; Daskalopoulou, S. S.; Elisaf, M. S.24-Nov-2015
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemiaMilionis, H. J.; Kakafika, A. I.; Tsouli, S. G.; Athyros, V. G.; Bairaktari, E. T.; Seferiadis, K. I.; Elisaf, M. S.24-Nov-2015
Fibrinogen: a predictor of vascular diseaseKakafika, A. I.; Liberopoulos, E. N.; Mikhailidis, D. P.24-Nov-2015
Hypouricemia in individuals admitted to an inpatient hospital-based facilityBairaktari, E. T.; Kakafika, A. I.; Pritsivelis, N.; Hatzidimou, K. G.; Tsianos, E. V.; Seferiadis, K. I.; Elisaf, M. S.24-Nov-2015
Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levelsAthyros, V. G.; Mikhailidis, D. P.; Kakafika, A. I.; Karagiannis, A.; Hatzitolios, A.; Tziomalos, K.; Ganotakis, E. S.; Liberopoulos, E. N.; Elisaf, M. S.24-Nov-2015
The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activityKakafika, A. I.; Xenofontos, S.; Tsimihodimos, V.; Tambaki, A. P.; Lourida, E. S.; Kalaitzidis, R.; Cariolou, M. A.; Elisaf, M.; Tselepis, A. D.24-Nov-2015
Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre StudyAthyros, V. G.; Mikhailidis, D. P.; Papageorgiou, A. A.; Didangelos, T. P.; Ganotakis, E. S.; Symeonidis, A. N.; Daskalopoulou, S. S.; Kakafika, A. I.; Elisaf, M. S.24-Nov-2015
The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?Karagiannis, A.; Mikhailidis, D. P.; Athyros, V. G.; Kakafika, A. I.; Tziomalos, K.; Liberopoulos, E. N.; Florentin, M.; Elisaf, M. S.24-Nov-2015
Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease PatientsAthyros, V. G.; Kakafika, A. I.; Papageorgiou, A. A.; Pagourelias, E. D.; Savvatianos, S. D.; Elisaf, M. S.; Karagiannis, A.; Tziomalos, K.; Mikhailidis, D. P.24-Nov-2015
Targeting vascular risk in patients with metabolic syndrome but without diabetesAthyros, V. G.; Mikhailidis, D. P.; Papageorgiou, A. A.; Didangelos, T. P.; Peletidou, A.; Kleta, D.; Karagiannis, A.; Kakafika, A. I.; Tziomalos, K.; Elisaf, M. S.24-Nov-2015